Lobo Ann-Marie, Sobrin Lucia, Papaliodis George N
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
Semin Ophthalmol. 2010 Sep-Nov;25(5-6):283-8. doi: 10.3109/08820538.2010.518522.
Treatments available for ocular inflammatory diseases and their associated complications have expanded significantly over the course of the last ten years. While corticosteroids are a mainstay of therapy for uveitis and macular edema, the methods of delivering corticosteroids have evolved. Intravitreal triamcinolone acetonide provides a local therapy for persistent cystoid macular edema (CME) and posterior uveitis. Other intravitreal therapies, such as bevacizumab and methotrexate, have also been used successfully in uveitic CME. Sustained release intravitreal implants, including the fluocinolone acetonide implant and the dexamethasone drug delivery system, offer an alternative therapy for chronic, recalcitrant posterior uveitis and CME. Their design was inspired by the ganciclovir implant, which prevented the progression of CMV retinitis in AIDS patients. Technological advances in drug delivery have supplied new treatments for patients with ocular inflammatory disease.
在过去十年中，可用于治疗眼部炎症性疾病及其相关并发症的方法有了显著扩展。虽然皮质类固醇是葡萄膜炎和黄斑水肿治疗的主要手段，但皮质类固醇的给药方式已经有所发展。玻璃体内注射曲安奈德为持续性黄斑囊样水肿（CME）和后葡萄膜炎提供了一种局部治疗方法。其他玻璃体内治疗方法，如贝伐单抗和甲氨蝶呤，也已成功用于葡萄膜炎性CME。包括醋酸氟轻松植入物和地塞米松给药系统在内的缓释玻璃体内植入物，为慢性、难治性后葡萄膜炎和CME提供了一种替代治疗方法。它们的设计灵感来自于更昔洛韦植入物，该植入物可防止艾滋病患者巨细胞病毒性视网膜炎的进展。药物递送技术的进步为眼部炎症性疾病患者提供了新的治疗方法。
